Banco Sabadell has decided to invest in the ‘biotech’ Gate2Brain, one of the startups awarded in the third edition of the Bstartup Health program, as explained in a statement on Tuesday.
Gate2Brain was created by researchers from IRB Barcelona, the University of Barcelona and the Institut d’Investigació de Sant Joan de Déu – Hospital Sant Joan de Déu, and has developed an innovative technology to transport drugs to the brain through the combination of several families of peptides that allow crossing the blood-brain barrier.
This barrier prevents access of up to 98% of drugs destined for the central nervous system and makes access to the brain “extremely complex.”
The CEO of Gate2Brain, Meritxell Teixidó, explained that this investment will allow “exploring how this technology can improve the transport of drugs to the brain to fight pediatric tumors”.
For her part, Marta Campillo, investment analyst at Bstartup, has been satisfied with “trusting in a ‘spin off’ that comes out of the university environment.”
Banco Sabadell’s current investment of 100,000 euros is the second investment formalized by the financial institution after selecting four companies in the third call for grants, aimed at validating technology, research and business through an investment of 100,000 euros and an accompaniment program.